* This study is being highlighted during a DDW press conference on Tuesday, June 2 at 9 a.m. CDT. Press conferences will be held in room N427A of the McCormick Place Convention Center.
Noting the importance of the studies in the late-breaking session, co-moderator Philip S. Schoenfeld, MD, MSEd, MSc (Epi), said, "These treatments will become the standard of care for their patients in the near future."
One abstract will present the results of a trial that re-treated hepatitis C patients who had previously failed treatment with pegylated interferon and ribavirin (patients received treatment with telaprevir combined with pegylated interferon and ribavirin).
Another abstract will present the results of the SONIC trial, which assessed whether adding azathioprine to infliximab in the treatment of Crohn's disease improved outcomes. "This is a very important study because people did not know if we should be combining azathioprine with infliximab. Now, we have data to guide this decision," Dr. Schoenfeld added.
During the AGA Institute Presidential Plenary Session, AGA Institute President, Robert S. Sandler, MD, MPH, AGAF, will focus on critical questions for gastroenterology. Two concurrent plenary sessions feature noteworthy clinical and basic science research presented at DDW.
The Presidential Plenary session presentations (Monday, June 1, 10 a.m. - noon CDT, Room B1) include:
|Contact: Alissa J. Cruz|
American Gastroenterological Association